Vivos (RDGL) Net Income towards Common Stockholders (QoQ) (2010 - 2025)
Vivos (RDGL) Net Income towards Common Stockholders (QoQ) (2010 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn |
| 10 | Vivos | 22.64 Mn | 21.08 Mn | -3,105.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -112.60% |
| Sep 30, 2025 | 21.41% |
| Jun 30, 2025 | 22.66% |
| Mar 31, 2025 | 18.42% |
| Dec 31, 2024 | -23.98% |
| Sep 30, 2024 | -63.92% |
| Jun 30, 2024 | 9.86% |
| Mar 31, 2024 | 48.10% |
| Dec 31, 2023 | -61.19% |
| Sep 30, 2023 | 26.02% |
| Jun 30, 2023 | -263.46% |
| Mar 31, 2023 | 64.81% |
| Dec 31, 2022 | -154.69% |
| Sep 30, 2022 | 64.82% |
| Jun 30, 2022 | -12.52% |
| Mar 31, 2022 | -292.70% |
| Dec 31, 2021 | 11.40% |
| Sep 30, 2021 | 89.19% |
| Jun 30, 2021 | -545.47% |
| Mar 31, 2021 | 4.60% |